Biotech Firms Histogenics and ProChon Merge (OTW)
Histogenics Acquires ProChon Biotech in an All-Stock Transaction (HealthPointCapital)
Histogenic acquired ProChon Biotech in an all-stock exchange this week, with the companies declining to announce a dollar amount for the transaction. Both companies are developing autologous cartilage regeneration products. Histogenics has begun phase III studies of its NeoCart product following "very positive" phase II data, while ProChon has fibroblast growth factor technology they were developing into the BioCart system. The company said their immediate goa...
